MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (CD205SHUTTLE)
Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma
Sponsor: Menarini Group
Terminated
Terminated after achievement of MTD, without progressing to cohort expansion for Company decision.
Other terminated trials from Menarini Group
- Acute Myeloid Leukemia, in Relapse · Phase PHASE1 · Apr 2021
- Surgical Site Infection · Phase PHASE3 · Oct 2020
- Tumor Lysis Syndrome · Phase PHASE1/PHASE2 · Jul 2018
- Irritable Bowel Syndrome With Diarrhea · Phase PHASE3 · Nov 2015
- Ovarian Cancer · Phase PHASE2/PHASE3 · Jun 2011
More terminations from Menarini Group
This PHASE1 trial investigates Metastatic Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma and is currently terminated or withdrawn. Menarini Group leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE1
▶ Show 8 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE1
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Oct 2019 — Apr 2020 [monthly]
Recruiting PHASE1
-
Feb 2019 — Oct 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Menarini Group
For direct contact, visit the study record on ClinicalTrials.gov .